Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 60
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Int Med Res ; 31(4): 290-8, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-12964504

RESUMEN

To clarify the risk factors for developing microalbuminuria in patients with type 2 diabetes mellitus, a longitudinal observational study was performed. Fifty patients with normoalbuminuria were recruited and treated conventionally for 9 years. Polymorphisms of the angiotensin-converting enzyme (ACE) gene and the angiotensinogen M235T polymorphism were examined. During the study period, 12 of the 50 patients developed microalbuminuria; no patients progressed to macroalbuminuria. Multiple logistic regression analysis was performed using age, duration of diabetes, body mass index, haemoglobin A1c' blood pressure, serum lipid profile and genetic polymorphisms as independent variables and development of microalbuminuria as the dependent variable. The D allele of the ACE gene was an independent and significant variable. We conclude that the ACE gene D allele polymorphism is a potent risk factor for developing microalbuminuria in type 2 diabetic patients.


Asunto(s)
Albuminuria/etiología , Diabetes Mellitus Tipo 2/complicaciones , Peptidil-Dipeptidasa A/genética , Polimorfismo Genético , Adulto , Anciano , Albuminuria/patología , Albuminuria/fisiopatología , Femenino , Estudios de Seguimiento , Frecuencia de los Genes , Genotipo , Humanos , Japón , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Peptidil-Dipeptidasa A/metabolismo , Análisis de Regresión , Factores de Riesgo
2.
J Int Med Res ; 29(5): 445-50, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11725834

RESUMEN

We report a case of recurrent pyogenic vertebral osteomyelitis associated with type 2 diabetes mellitus. A 51-year-old male was admitted to our hospital because of lumbago and general fatigue, with multiple ulcers on the soles of his feet. Staphylococcus aureus was isolated from peripheral blood and the foot ulcers, and 67Gallium scintigram showed abnormal isotope uptake, accumulated at the lower thoracic spine. Antibiotics were administered and the patient underwent intensive insulin therapy. Magnetic resonance imaging (MRI), performed after the levels of C-reactive protein decreased to 0.0 mg/dl, indicated old inflammatory changes at the Th8-Th9 spine and antibiotics were stopped. Unexpectedly, 8 days later the patient complained of lumbago with fever again, and MRI showed acute inflammatory changes at the same lesion site. This case report suggests that it is important for complementary antibiotic therapy to continue after signs of inflammation have disappeared in cases of pyogenic vertebral osteomyelitis.


Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Osteomielitis/diagnóstico , Enfermedades de la Columna Vertebral/diagnóstico , Pie Diabético/diagnóstico , Pie Diabético/microbiología , Ecocardiografía , Fatiga/etiología , Humanos , Dolor de la Región Lumbar/etiología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Osteomielitis/etiología , Recurrencia , Enfermedades de la Columna Vertebral/etiología , Infecciones Estafilocócicas/diagnóstico , Resultado del Tratamiento
3.
J Int Med Res ; 29(4): 280-6, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11675900

RESUMEN

This 7-year retrospective longitudinal study was carried out in order to clarify the clinical features of elderly type 2 diabetic patients with microalbuminuria. Elderly Japanese type 2 diabetic patients (n = 22; age 50 - 73 years) with microalbuminuria were studied retrospectively. Patients whose urinary albumin excretion rate (UAER) decreased 7 years were considered 'nonprogressors' (n = 8) whereas those whose UAER increased were considered 'progressors' (n = 14). The mean 7-year level of glycosylated haemoglobin (HbA1c) did not differ significantly between non-progressors and progressors but the mean 7-year blood pressure (BP) of progressors (101 +/- 8 mmHg) was significantly higher than that of non-progressors (92 +/- 7 mmHg). In progressors who received no anti-hypertensive drugs, systolic BP was above the BP goal of 130/85 mmHg but mean BP and diastolic BP were below this goal. The results are consistent with the view that hypertension affects the progression of microalbuminuria; raised systolic BP may be a factor in this progression in elderly type 2 diabetic patients.


Asunto(s)
Albuminuria/etiología , Albuminuria/fisiopatología , Presión Sanguínea/fisiología , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/fisiopatología , Anciano , Antihipertensivos/uso terapéutico , Apolipoproteínas E/sangre , Apolipoproteínas E/genética , Nefropatías Diabéticas/etiología , Nefropatías Diabéticas/fisiopatología , Nefropatías Diabéticas/prevención & control , Femenino , Estudios de Seguimiento , Humanos , Hipertensión/complicaciones , Hipertensión/tratamiento farmacológico , Hipertensión/fisiopatología , Japón , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Fenotipo , Estudios Retrospectivos , Factores de Riesgo
5.
Phys Rev Lett ; 86(26 Pt 1): 6026-9, 2001 Jun 25.
Artículo en Inglés | MEDLINE | ID: mdl-11415420

RESUMEN

We test whether the complexity of the cardiac interbeat interval time series is simply a consequence of the wide range of scales characterizing human behavior, especially physical activity, by analyzing data taken from healthy adult subjects under three conditions with controls: (i) a "constant routine" protocol where physical activity and postural changes are kept to a minimum, (ii) sympathetic blockade, and (iii) parasympathetic blockade. We find that when fluctuations in physical activity and other behavioral modifiers are minimized, a remarkable level of complexity of heartbeat dynamics remains, while for neuroautonomic blockade the multifractal complexity decreases.


Asunto(s)
Corazón/fisiología , Actividades Cotidianas , Antagonistas Adrenérgicos beta/farmacología , Adulto , Atropina/farmacología , Femenino , Fractales , Corazón/efectos de los fármacos , Corazón/inervación , Humanos , Masculino , Metoprolol/farmacología , Sistema Nervioso Parasimpático/efectos de los fármacos , Sistema Nervioso Parasimpático/fisiología , Parasimpatolíticos/farmacología , Sistema Nervioso Simpático/efectos de los fármacos , Sistema Nervioso Simpático/fisiología
6.
Metabolism ; 49(9): 1118-23, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-11016890

RESUMEN

We have recently identified a novel gene, klotho (kl), which may suppress several aging phenotypes. A defect of kl gene expression in the mouse results in a syndrome resembling human aging, such as arteriosclerosis, skin atrophy, osteoporosis, and pulmonary emphysema. To determine whether mouse homozygotes for the kl mutation (kl/kl) show abnormal glucose metabolism, an oral glucose tolerance test (OGTT) was performed at 6 to 8 weeks of age. Blood glucose levels during the OGTT were significantly lower in kl/kl mice versus wild-type mice. The insulin content of the pancreas was significantly lower in kl/kl mice compared with wild-type mice. Decreased insulin production was also supported by Northern blot analysis showing lower levels of insulin mRNA in kl/kl mice. To examine how lower blood glucose levels may exist in kl/kl mice despite decreased insulin production, insulin tolerance tests (ITTs) were performed. The glucose decline following insulin injection was more severe in kl/kl mice versus wild-type mice, suggesting that insulin sensitivity was higher in kl/kl mice versus wild-type mice. In kl/kl mice, an augmented expression of GLUT4 in skeletal muscle was demonstrated by both Northern blot analysis and Western blot analysis. Thus, we conclude that insulin production is decreased and insulin sensitivity is increased in the klotho mouse, a novel animal model for human aging.


Asunto(s)
Envejecimiento/fisiología , Insulina/sangre , Insulina/farmacología , Modelos Biológicos , Proteínas Musculares , Hormona Adrenocorticotrópica/sangre , Animales , Glucemia/análisis , Expresión Génica , Prueba de Tolerancia a la Glucosa , Transportador de Glucosa de Tipo 4 , Hormona del Crecimiento/sangre , Humanos , Hipoglucemia/metabolismo , Islotes Pancreáticos/anatomía & histología , Islotes Pancreáticos/metabolismo , Ratones , Ratones Mutantes , Proteínas de Transporte de Monosacáridos/genética , Proteínas de Transporte de Monosacáridos/metabolismo , Músculo Esquelético/metabolismo , ARN Mensajero/análisis , Tirotropina/sangre
9.
Eur J Pharmacol ; 398(3): 409-14, 2000 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-10862831

RESUMEN

We investigated the therapeutic effect of branched chain amino acids (BCAA) on mice with glucose intolerance induced by encephalomyocarditis virus (EMCV). Male DBA/2 mice were divided into three groups: treated with BCAA, (such as valine, leucine, and isoleucine), untreated, and control. BCAA-treated and -untreated groups were inoculated intraperitoneally with the NDK25 variant of EMCV at 200 plaque-forming units per mouse. The BCAA-treated group was administered orally 0.9 g/kg/day of each BCAA from the day after viral inoculation. The control group neither received virus inoculation nor was treated with BCAA. One week after inoculation, oral glucose tolerance tests (OGTT) were performed. After the glucose loading at 1.5 g/kg of body weight, blood glucose levels in the untreated group were 92.0+/-10.0 mg/dl at baseline, 224.6+/-10.9 mg/dl at 30 min, and 169.4+/-21.4 mg/dl at 60 min, which were significantly (P<0.05) higher than those in the control group (62. 7+/-3.6 mg/dl, 167.2+/-16.4, and 83.8+/-6.0 mg/dl, respectively). Blood glucose levels in the BCAA-treated group were 54.5+/-3.7 mg/dl at baseline, 145.2+/-8.7 mg/dl at 30 min, and 128.7+/-18.3 mg/dl at 60 min after the glucose loading, which were not significantly higher than those in the control group. Immunoreactive insulin levels at 30 min after the glucose loading were lower in the untreated group than in the control group at 1 week after virus inoculation. Histological investigations showed that the grade of insulitis in the pancreas of mice of the BCAA-treated group was lower than that of the mice of the untreated group. These results suggest that oral administration of BCAA is able to improve glucose intolerance induced by EMCV.


Asunto(s)
Aminoácidos de Cadena Ramificada/uso terapéutico , Intolerancia a la Glucosa/tratamiento farmacológico , Administración Oral , Aminoácidos de Cadena Ramificada/farmacología , Animales , Glucemia/efectos de los fármacos , Infecciones por Cardiovirus , Virus de la Encefalomiocarditis , Intolerancia a la Glucosa/virología , Masculino , Ratones , Ratones Endogámicos DBA , Páncreas/efectos de los fármacos , Páncreas/patología
10.
Arterioscler Thromb Vasc Biol ; 20(4): 1155-61, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10764687

RESUMEN

A decline in oxygen concentration perturbs endothelial function, which promotes local thrombosis. In this study, we determined whether hypoxia in the range of that observed in pathophysiological hypoxic states stimulates plasminogen activator inhibitor-1 (PAI-1) production in bovine aortic endothelial cells. PAI-1 production, measured by ELISA, was increased by 4.7-fold (P<0.05 versus normoxic control, n=4) at 12 hours after hypoxic stimulation. Northern blot analysis showed the progressive time-dependent increase in the steady-state level of PAI-1 mRNA expression by hypoxia, which reached a 7.5-fold increase (P<0.05 versus control, n=4) at 12 hours. Deferoxamine, which has been known to bind heme protein and to reproduce the hypoxic response, induced PAI-1 production at both the mRNA and protein levels. The half-life of PAI-1 mRNA, as determined by a standard decay assay, was not affected by hypoxia, suggesting that induction of PAI-1 mRNA was regulated mainly at the transcriptional level. Transient transfection assays of the human PAI-1 promoter-luciferase construct indicates that a hypoxia-responsive region lies between -414 and -107 relative to the transcription start site, where no putative hypoxia response element is found. The hypoxia-mediated increase in PAI-1 mRNA levels was attenuated by the tyrosine kinase inhibitors genistein (50 micromol/L) and herbimycin A (1 micromol/L), whereas PD98059 (50 micromol/L, MEK1 inhibitor), SB203580 (10 micromol/L, p38 mitogen-activated protein kinase inhibitor), and calphostin C (1 micromol/L, protein kinase C inhibitor) had no effect on the induction of PAI-1 expression by hypoxia and deferoxamine. Genistein but not daidzein blocked the production of hypoxia- and deferoxamine-induced PAI-1 protein. Thus, we conclude that hypoxia stimulates PAI-1 gene transcription and protein production through a signaling pathway involving genistein-sensitive tyrosine kinases in vascular endothelial cells.


Asunto(s)
Hipoxia de la Célula , Endotelio Vascular/metabolismo , Genisteína/farmacología , Inhibidor 1 de Activador Plasminogénico/genética , Proteínas Tirosina Quinasas/metabolismo , Transcripción Genética , Animales , Aorta , Benzoquinonas , Northern Blotting , Bovinos , Células Cultivadas , Deferoxamina/farmacología , Inhibidores Enzimáticos/farmacología , Ensayo de Inmunoadsorción Enzimática , Expresión Génica/efectos de los fármacos , Lactamas Macrocíclicas , Regiones Promotoras Genéticas , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Quinonas/farmacología , ARN Mensajero/metabolismo , Proteínas Recombinantes de Fusión , Rifabutina/análogos & derivados , Transcripción Genética/efectos de los fármacos , Transfección
11.
Am J Physiol Heart Circ Physiol ; 278(4): H1035-41, 2000 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10749695

RESUMEN

A newly developed, very long-term ( approximately 7 days) ambulatory monitoring system for assessing beat-to-beat heart rate variability (HRV) and body movements (BM) was used to study the mechanism(s) responsible for the long-period oscillation in human HRV. Data continuously collected from five healthy subjects were analyzed by 1) standard auto- and cross-spectral techniques, 2) a cross-Wigner distribution (WD; a time-frequency analysis) between BM and HRV for 10-s averaged data, and 3) coarse-graining spectral analysis for 600 successive cardiac cycles. The results showed 1) a clear circadian rhythm in HRV and BM, 2) a 1/f (beta)-type spectrum in HRV and BM at ultradian frequencies, and 3) coherent relationships between BM and HRV only at specific ultradian as well as circadian frequencies, indicated by significant (P < 0.05) levels of the squared coherence and temporal localizations of the covariance between BM and HRV in the cross-WD. In a single subject, an instance in which the behavioral (mean BM) and autonomic [HRV power >0.15 Hz and mean heart rate (HR)] rhythmicities were dissociated occurred when the individual had an irregular daily life. It was concluded that the long-term HRV in normal humans contained persistent oscillations synchronized with those of BM at ultradian frequencies but could not be explained exclusively by activity levels of the subjects.


Asunto(s)
Ritmo Circadiano/fisiología , Electrocardiografía Ambulatoria/métodos , Frecuencia Cardíaca/fisiología , Movimiento/fisiología , Adulto , Algoritmos , Femenino , Humanos , Masculino , Factores de Tiempo , Nervio Vago/fisiología
12.
Nihon Ronen Igakkai Zasshi ; 35(3): 25-8, 1998 Mar.
Artículo en Japonés | MEDLINE | ID: mdl-9597883

RESUMEN

Senile dementia of Alzheimer's type (SDAT) is reported to be less frequent in patients with Diabetes Mellitus. However the, the number of elderly people in still increasing in Japan, an is the incidence of diabetes mellitus, especially in middle-aged and elderly people. Thus, we can expect to encounter more elderly people with diabetes and SDAT. We encountered three patients with diabetes who were treated with insulin and in whom SDAT developed. In all three, control of blood glucose levels gradually worsened, despite increases in the dose of injected insulin. It was later found that they did not inject insulin properly because of SDAT. They lived alone and their dementia was not diagnosed before their admission to the hospital. In its early phase, SDAT can be difficult to diagnose, especially in patients who live alone. SDAT should be considered when the control of blood glucose levels for no apparent reason in elderly patients with diabetes.


Asunto(s)
Enfermedad de Alzheimer/complicaciones , Complicaciones de la Diabetes , Diabetes Mellitus/tratamiento farmacológico , Insulina/uso terapéutico , Anciano , Anciano de 80 o más Años , Femenino , Humanos
13.
Eur J Pharmacol ; 342(2-3): 297-302, 1998 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-9548400

RESUMEN

We investigated the therapeutic effects of OK432 (picibanil; CAS39325-1-4), an immunomodulator that is derived from the Su strain of Streptococcus pyogenes. This agent was administered alone or combined with human interferon-alpha in a murine model of insulin-dependent diabetes mellitus. Interferon-alpha inhibits viral replication, reducing the incidence of virus-induced IDDM. Groups of DBA/2 mice (N = 25 per group) received an intraperitoneal injection of OK432 and interferon-alpha daily for 16 d beginning 1 d after inoculation with 500 plaque-forming units of encephalomyocarditis virus (EMCV). The dose of OK432 was one clinical unit (corresponding to 0.1 mg dried cells) per mouse, and that of interferon-alpha was 1 x 10(4) u/g. The animals were killed at random at 3 or 7 d after inoculation with EMCV. The survival rate of mice treated with the combination of OK432 and with interferon-alpha was significantly greater than that of the non-treated infected control animals (P < 0.01). Fasting levels of blood glucose were significantly lower in the mice administered the combination, than in the controls, both on day 3 (68 +/- 21 mg/dl vs. 270 +/- 135 mg/dl, P < 0.01) and on day 7 (101 +/- 29 mg/dl vs. 219 +/- 112 mg/dl, P < 0.01). Serum levels of insulin were significantly higher in the treated mice than in the controls (65 +/- 5 vs. 55 +/- 1 microU/ml, P < 0.05). However, in the mice treated with OK432 or interferon-alpha alone, the survival rate and the blood level of glucose and insulin did not differ from those of infected controls. Natural killer (NK) cell activity was significantly higher in the mice treated with the drug combination than in the controls on both days evaluated: day 3, 65 +/- 5 vs. 55 +/- 1%, n = 3, P < 0.05; day 7, 44 +/- 3 vs. 22 +/- 8%, n = 3, P < 0.05). Serum levels of murine interferon in the treated mice exceeded those in controls on both days evaluated (day 3, 671 U/ml vs. 442 U/ml; day 7, 57 U/ml vs. 43 U/ml). There were no significant differences in NK cell activity or in the interferon level in mice treated with either OK432 or interferon-alpha alone as compared with the infected, non-treated controls. Results suggest that the combination of OK432 and interferon-alpha protects against virally induced IDDM by increasing the activity of NK cells as well as the plasma level of interferon.


Asunto(s)
Infecciones por Cardiovirus/complicaciones , Diabetes Mellitus Experimental/tratamiento farmacológico , Virus de la Encefalomiocarditis , Interferón Tipo I/farmacología , Picibanil/farmacología , Animales , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Infecciones por Cardiovirus/patología , Infecciones por Cardiovirus/virología , Supervivencia Celular/efectos de los fármacos , Diabetes Mellitus Experimental/patología , Diabetes Mellitus Experimental/virología , Insulina/sangre , Interferones/sangre , Células Asesinas Naturales/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos DBA , Páncreas/patología , Páncreas/virología , Proteínas Recombinantes , Análisis de Supervivencia
15.
Horm Metab Res ; 29(1): 9-11, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9049646

RESUMEN

Plasma 1,5-anhydro-D-glucitol (AG) is a marker of the diabetic state and also reflects the glycosuria induced by hyperglycemia but not by renal pathology. To investigate the benefits of the AG determination in order to diagnose diabetes in BB/Wor/(/)Tky rats, AG was measured in non-diabetic (n = 104) and diabetic (n = 113) BB/Wor/(/)Tky rats. AG was significantly higher in non-diabetic rats than in diabetic rats (25.2 +/- 9.3 vs 4.1 +/- 7.4 micrograms/ ml, mean +/- SD, p < 0.001). The best cut-off level for AG (8.5 micrograms/ml) was highly specific (100%) for ruling out diabetes and fairly sensitive (82.3%) to detect diabetes. Based on the AG cut-off levels, 90% of false-negative diabetic rats (18/20) were observed within 4 days after the onset of diabetes, which corresponded to 38.3% in diabetic rats (18/47) at that time. The false-negative diabetic rats and positive rats could be effectively distinguished based on the cumulative points given according to the urinary glucose after the onset of diabetes. 1 point for each cross [+] indicating glycosuria using the Testape, i.e. 2 or less points false negative and 4 or more points for diabetic rats in the first 4 days. In conclusion, there is a close inverse relation between the level of plasma AG and the amount of glycosuria detected just after the onset of overt diabetes in BB/Wor/(/)Tky rats.


Asunto(s)
Desoxiglucosa/sangre , Diabetes Mellitus/sangre , Animales , Biomarcadores/sangre , Glucemia/metabolismo , Glucosuria/sangre , Ratas , Ratas Endogámicas , Sensibilidad y Especificidad
16.
Nihon Rinsho ; 54(10): 2692-9, 1996 Oct.
Artículo en Japonés | MEDLINE | ID: mdl-8914429

RESUMEN

Those who have IGT (impaired glucose tolerance) are thought to be highly risky to atherosclerotic coronary artery disease (CAD), probably because of the frequent association with insulin resistance or hyperinsulinemia, obesity or abdominal fat accumulation, hypertriglyceridemia and so on. Whether insulin resistance which is one of the major causes of IGT, following hyperglycemia itself or both is really responsible for CAD is remained to be clarified. Furthermore, IGT is also an apparent candidate for NIDDM in future. Thus, IGT should be intensively treated to prevent or delay the onset of NIDDM and also to minimize the adverse events by atherosclerotic CAD.


Asunto(s)
Enfermedad Coronaria/etiología , Enfermedad Coronaria/prevención & control , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/prevención & control , Intolerancia a la Glucosa/complicaciones , Humanos , Hiperglucemia/complicaciones , Hiperinsulinismo/complicaciones , Resistencia a la Insulina , Obesidad/complicaciones , Factores de Riesgo
17.
Intern Med ; 35(2): 94-9, 1996 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8680112

RESUMEN

The association between the lack of adrenergic symptoms during hypoglycemia and myocardial 123I-metaiodobenzylguanidine (MIBG) accumulation was investigated in 12 insulin-treated non-insulin-dependent diabetes mellitus (NIDDM) patients who had no evidence of heart disease. These patients were divided into 2 groups according to the presence (group A) or absence (group B) of adrenergic symptoms during hypoglycemia. Autonomic function tests revealed significantly severe autonomic dysfunction in group B compared to that in group A. Insulin infusion test indicated no significant difference in the catecholamine response between the two groups. 123I-MIBG scintigraphy showed that the heart/mediastinum ratio of MIBG uptake was significantly lower, and scintigraphic defect was greater in group B than in group A. There were no significant differences in the washout rate between the two groups. These results suggested that the lack of adrenergic symptoms during hypoglycemia may be associated with cardiac sympathetic nervous dysfunction in insulin-treated NIDDM patients, and this dysfunction is mainly due to cardiac sympathetic denervation.


Asunto(s)
Diabetes Mellitus Tipo 2/fisiopatología , Corazón/inervación , Hipoglucemia/fisiopatología , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Yodobencenos , Sistema Nervioso Simpático/fisiopatología , Simpaticolíticos , 3-Yodobencilguanidina , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Epinefrina/sangre , Corazón/diagnóstico por imagen , Pruebas de Función Cardíaca , Humanos , Hipoglucemia/sangre , Hipoglucemia/inducido químicamente , Hipoglucemiantes/efectos adversos , Inyecciones Intravenosas , Insulina/efectos adversos , Radioisótopos de Yodo , Persona de Mediana Edad , Norepinefrina/sangre , Percepción , Cintigrafía , Sistema Nervioso Simpático/diagnóstico por imagen
18.
Metabolism ; 45(2): 218-22, 1996 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8596493

RESUMEN

To investigate predictive genetic markers for diabetic nephropathy, we studied the genetic polymorphisms of angiotensin-converting enzyme (ACE) and angiotensinogen (AGN) in Japanese subjects with non-insulin-dependent diabetes mellitus (NIDDM) with and without nephropathy. Genotype distributions were studied in 132 unrelated NIDDM patients of three groups with normoalbuminuria ([Normo] n = 53), microalbuminuria ([Micro] n = 54), and macroalbuminuria ([Macro] n = 25). The ACE insertion/deletion (I/D) polymorphism of intron 16 was identified by polymerase chain reaction, and the AGN M235T polymorphism was identified by restriction fragment length polymorphism analysis. There were no significant associations between AGN 235 allele or genotype and diabetic nephropathy. The D allele of ACE was significantly more frequent in the Micro (P = .003) and Macro (P = .009) group than in the Normo group. Overall frequencies of the ACE genotype did not differ significantly between the Micro and Macro groups. There were significant relationships between I/D polymorphism and plasma ACE activity; the DD genotype had the highest activity. A multiple logistic regression analysis revealed that the D allele is a strong and independent risk factor for abnormal albuminuria in NIDDM patients. These results suggested that ACE I/D polymorphism, but not AGN M235T polymorphism, is a possible genetic risk factor for diabetic nephropathy in Japanese NIDDM patients.


Asunto(s)
Albuminuria/genética , Angiotensinógeno/genética , Diabetes Mellitus Tipo 2/genética , Nefropatías Diabéticas/genética , Peptidil-Dipeptidasa A/genética , Anciano , Albuminuria/enzimología , Alelos , Secuencia de Bases , Estudios de Casos y Controles , Diabetes Mellitus Tipo 2/enzimología , Nefropatías Diabéticas/enzimología , Femenino , Genotipo , Humanos , Modelos Logísticos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Reacción en Cadena de la Polimerasa , Polimorfismo Genético , Factores de Riesgo
19.
Diabetes Care ; 19(1): 8-11, 1996 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-8720525

RESUMEN

OBJECTIVE: To determine the secretion of insulin, C-peptide, and proinsulin after oral glucose loading in healthy elderly subjects compared with middle-aged subjects with and without obesity and with NIDDM. RESEARCH DESIGN AND METHODS: Subjects fell into four groups: nonobese middle-aged normal control subjects (CNT group; n = 38, 40-64 years old); obese normal subjects (OB group; n = 18, 40-64 years old); nonobese NIDDM subjects (NIDDM group; n = 28, 40-64 years old); and nonobese elderly subjects (OL group; n = 17, 65-92 years old). Insulin, C-peptide, and proinsulin were determined by radioimmunoassay in plasma samples taken at 0, 30, 60, and 120 min during a 75-g oral glucose tolerance test (OGTT). RESULTS: There were no differences in plasma glucose during the OGTT among the three nondiabetic groups. Hyperinsulinemia was significant in the OB and NIDDM groups but not in the OL group. On the other hand, absolute hyperproinsulinemia was significant in the OL and NIDDM groups compared with the CNT group. Increased proinsulin was rather dominant in the OL group, especially late after glucose loading. Molar ratios of proinsulin to insulin or C-peptide thus were significantly higher in the OL and NIDDM groups. CONCLUSIONS: Alteration of pancreatic beta-cell function independent of that seen with NIDDM occurred in relation to aging. This may be a predisposing factor to the development of impaired glucose tolerance or NIDDM in elderly subjects, that is, independent of obesity.


Asunto(s)
Envejecimiento/fisiología , Diabetes Mellitus Tipo 2/fisiopatología , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Obesidad/fisiopatología , Adulto , Anciano , Anciano de 80 o más Años , Glucemia/metabolismo , Péptido C/sangre , Diabetes Mellitus Tipo 2/sangre , Intolerancia a la Glucosa , Prueba de Tolerancia a la Glucosa , Humanos , Insulina/sangre , Secreción de Insulina , Islotes Pancreáticos/crecimiento & desarrollo , Persona de Mediana Edad , Obesidad/sangre , Proinsulina/sangre , Valores de Referencia
20.
Endocr J ; 42(5): 649-53, 1995 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-8574288

RESUMEN

We examined the expression of reg protein in neonatal rat pancreas treated with streptozotocin (STZ) by means of the immunohistochemical technique and northern blotting. Seven days after STZ injection, the plasma glucose levels in STZ-treated neonatal rats were significantly higher than those in control rats. Scattered distribution of reg protein in pancreatic islet cells was clearly observed in STZ-treated rats, but not in control rats. On the other hand, reg proteins was positively stained in the exocrine cells in both groups of rats. Northern blot analyses revealed that the expression of insulin mRNA markedly decreased in STZ-treated rat pancreas, but a significant increase in reg mRNA expression was recognized in the STZ-treated rat pancreas compared with that of control rats. Rats treated with STZ during the neonatal period have been used as a model of non-insulin-dependent diabetes mellitus (NIDDM) and beta cell regeneration. Thus, the increased reg gene expression in neonatal STZ-treated rat pancreas was therefore described for the first time, and thus would be a useful model for studying the relationship between NIDDM and beta cell regeneration or reg gene protein.


Asunto(s)
Proteínas de Unión al Calcio/efectos de los fármacos , Diabetes Mellitus Experimental/metabolismo , Insulina/metabolismo , Islotes Pancreáticos/metabolismo , Proteínas del Tejido Nervioso , ARN Mensajero/análisis , Estreptozocina/farmacología , Animales , Animales Recién Nacidos , Northern Blotting , Proteínas de Unión al Calcio/genética , Proteínas de Unión al Calcio/metabolismo , Inmunohistoquímica , Insulina/genética , Litostatina , Ratas , Ratas Wistar , Regulación hacia Arriba/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA